ArticleAntimicrobial agents and chemotherapy2009
Bronchopulmonary disposition of micafungin in healthy adult volunteers.
Article in Antimicrobial agents and chemotherapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 32 citations in OpenAlex.
- Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients.Antimicrobial agents and chemotherapy · 2010Trial
- Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults.Antimicrobial agents and chemotherapy · 2009Trial
- Human Tissue Distribution of Anidulafungin and Micafungin.Antimicrobial agents and chemotherapy · 2021Article
- Mutant Prevention Concentration and Mutant Selection Window of Micafungin and Anidulafungin in Clinical Candida glabrata Isolates.Antimicrobial agents and chemotherapy · 2018Article
- Clinical Pharmacokinetics and Pharmacodynamics of Micafungin.Clinical pharmacokinetics · 2018Review
- Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Infection · 2017Review
- Tissue penetration of antifungal agents.Clinical microbiology reviews · 2014Review
- Micafungin for Candida albicans pacemaker-associated endocarditis: a case report and review of the literature.Mycopathologia · 2013Review
- Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections.Drugs · 2012Review
- Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents.Clinical pharmacokinetics · 2011Review
- Review
- Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry.Antimicrobial agents and chemotherapy · 2010Article
- Pulmonary epithelial lining fluid concentrations after use of systemic amphotericin B lipid formulations.Antimicrobial agents and chemotherapy · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
By way of bronchoscopy and bronchoalveolar lavage, intrapulmonary steady-state concentrations of micafungin administered at 150 mg daily to 15 healthy volunteers were determined at 4, 12, and 24 h after the third dose. The micafungin disposition was predominantly intracellular, with approximately 106% penetration into alveolar macrophages and 5% penetration into epithelial lining fluid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.